Navigation Links
Baxter Presents Phase I Inhaled Insulin Study Results at,Respiratory Drug Delivery Conference

Findings Suggest Insulin Powder Produced Using Baxter's PROMAXX Microsphere Technology was Absorbed Systemically with No Reported Cough or Shortness of Breath

PARIS, April 20, 2007 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation announced results of a Phase I study that evaluated pulmonary insulin produced with Baxter's PROMAXX microsphere technology and administered using a small, standard dry powder inhaler. Baxter presented the Phase I data earlier this week at the Respiratory Drug Delivery Europe 2007 Conference in Paris.

The study demonstrates that the insulin powder can be effectively administered to the deep lung using an off-the-shelf dry powder inhaler designed for upper airway drug delivery. A total of 30 subjects participated in the randomized, two-way crossover study conducted in Germany. Each subject received in randomized fashion a single dose of 10 International Units of insulin through subcutaneous injection (SC) in one period, and 6.5 milligrams of the inhaled insulin microspheres, called recombinant human insulin inhalation powder (RHIIP) in the other period.

RHIIP is made using Baxter's proprietary PROMAXX formulation technology. Unlike other dry powder formulations of insulin, RHIIP is 95 percent insulin and does not rely on the use of inactive ingredients to facilitate delivery to the deep lung. In this study, no serious adverse events were reported and no subjects withdrew from the study due to an adverse event. All adverse events were mild in severity. The most common reported treatment-emergent adverse event was phlebitis. There were no reported episodes of cough or shortness of breath in this study.

Study data show that RHIIP had a faster onset of action than SC (time to reach 10 percent of total area under the glucose infusion rate (GIR) curve 73 vs 95 min.; GIR-tmax 173 versus 218 min., p<0.0001). Duration of action (371 vs 366 min.) and total metabolic ef
'"/>




Page: 1 2 3

Related medicine technology :

1. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ ... its CytoSorb® extracorporeal cytokine adsorber to reduce deadly ... the receipt of $385,642, net of transaction costs, ... the Technology Business Tax Certificate Transfer Program sponsored ...
(Date:1/23/2015)... , January 23, 2015 Heptares Therapeutics, the ... to announce that the Malcolm Campbell Memorial Prize ... (Vice President of Chemistry), Fiona Marshall (Chief Scientific ... Officer and co-founder) for the seminal contributions to GPCR drug ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to announce ... Vice President of Chemistry and Biochemistry. Scott joins the company ... Pharmaceuticals, and Amgen throughout the course of his nearly ... "Scott is a nationally recognized thought leader in ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
(Date:1/22/2015)... 23, 2015 The U.S. Pharmacopeial Convention ... Director of Clinical Pharmacy Services at North Carolina State’s ... of the 2015 Beal Award for Distinguished Volunteer Service—the ... relied on the contributions of volunteer experts to direct ...
(Date:1/22/2015)... The City of West Hollywood hosted a news conference ... 42nd anniversary of the Supreme Court decision Roe v. Wade, which ... since the Roe vs. Wade decision and the fight to protect ... said City of West Hollywood Councilmember Abbe Land. “We need to ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in ... Player Health Alliance (PPHA). The PPHA's passion for others' ... including NFL greats, treated for obstructive sleep apnea (OSA) has ... the cause in the valley. The most recent plans for ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many ... it on Facebook, Twitter, and Pinterest. The fans will have ... a lottery every week. , Moreover, the company has extended ... Angelweddingdress homepage for more information. , Angelweddingdress ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... 11 The Substance Abuse and,Mental Health Services ... Survey on Drug Use and Health (NSDUH) indicate,3.1 ... to 25 have abused non-prescription,over-the- counter (OTC) cough ... once,in their lifetime. This announcement and the data ...
... announced,today that a new generic prescription drug program will ... drugstores., The program offers a 30-day supply of ... The medicines on the list include antibiotics and drugs,that ... digestive issues., There are no forms to fill ...
... system should fight tumors, researchers say , , FRIDAY, ... fight ovarian and breast cancer are in the ... safety and effectiveness, researchers report. , The vaccine ... an assistant professor at the University of Pennsylvania,s ...
... aging and the declining health,status of the 78 ... in the United States, U.S. Preventive Medicine, Inc. ... years ahead., "According to a recent Forrester ... include wellness and disease management,programs in their health ...
... the ... BOLINGBROOK, Ill., Jan. 11 The first new ... open its doors on Monday,January 14. After three years ... reviews from the Illinois,Department of Public Health and is ...
... to make sure people are adequately informed about the ... trial can be field-tested for effectiveness as vigorously as ... Johns Hopkins bioethicist suggests. , Informed consent, ... by which potential research subjects are asked to decide ...
Cached Medicine News:Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse 3Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse 4Health News:Hy-Vee Unveils New Generic Drug Program 2Health News:Vaccines for Ovarian and Breast Cancer in Early Trials 2Health News:Vaccines for Ovarian and Breast Cancer in Early Trials 3Health News:U.S. Preventive Medicine(R) Predicts Robust Growth Ahead 2Health News:Adventist Bolingbrook Hospital Opens to the Public 2Health News:Ways to improve informed consent are testable, study says 2
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
... therapeutic, expandable turning surface for the BariMaxx™ ... Prevention and treatment of pressure ulcers, Large ... patients using a statuc mattress that would ... whose body weight and size pose a ...
... The BariMaxx™ is a full-featured healthcare bed ... for the care and management of larger ... to 1000 lbs. ,Large patients at risk ... in excess of 1000 lbs. (including accessories), ...
... feature folding head end and foot end deck panels ... end and foot end deck panels folded the overall ... This compact length makes storage, delivery and pick up ... not available on Model 4748B, Basic Maxi Rest bariatric ...
Medicine Products: